Updating Our Thoughts On Celgene

3/15/18

Image Source: Celgene Q4 2017 earnings presentation.

Pipeline Woes Continue

The share price of Celgene (CELG) was accelerating heading into the Fall of 2017 as the strength of its existing oncology pipeline coupled with a few late-stage molecules augured well for a continued advance in the share price.

The costly discontinuation of Mongersen cast doubt on Celgene’s ability to hit its long-term sales and earnings targets. Celgene, unlike its competitors in the biotech space, namely Gilead Sciences (GILD), remained a darling on the Street as the management team at Celgene would promote an earnings “roadmap” that assumed the approval of key pipeline assets, in direct contrast to the more reserved team at Gilead that would avoid such proclamations, in our view.

READ FULL ARTICLE HERE